Literature DB >> 22521204

Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic.

Elena B Hawryluk1, Arthur J Sober, Adriano Piris, Rosalynn M Nazarian, Mai P Hoang, Hensin Tsao, Martin C Mihm, Lyn M Duncan.   

Abstract

BACKGROUND: The histopathologic diagnosis of some melanocytic tumors is extraordinarily difficult. With this in mind, melanocytic tumors from patients referred to the Massachusetts General Hospital (MGH) Pigmented Lesion Clinic (PLC) are routinely reviewed in the MGH Dermatopathology Unit.
OBJECTIVE: We sought to determine the frequency of diagnostically challenging cases from patients treated at the MGH PLC, as measured by a change in the diagnosis upon review of the referral materials.
METHODS: We retrospectively reviewed the MGH and referral pathology reports for 478 consecutive cutaneous melanocytic tumors: 126 from 1996-1997 and 352 from 2010-2011. Differences in diagnosis and in therapeutic impact were evaluated.
RESULTS: Changes in diagnosis occurred in 168 of 478 cases (35%), more frequently when the original diagnostician was a general pathologist (P = .003). A similar fraction of diagnoses were changed from malignant to benign or vice versa, in both historic and contemporary cohorts. In 64 patients (13%), changes in diagnosis led to a change in therapy. Changes in stage or grading led to the most changes in therapy (78%; 50/64) versus changes from benign to malignant or vice versa (22%; 14/64). LIMITATIONS: This is a retrospective study with the bias of a tertiary-care referral center.
CONCLUSIONS: These findings demonstrate the diagnostic difficulty of a subset of melanocytic tumors and highlight the utility of review by more than one pathologist; patient treatment is affected in more than 10% of cases. Identification of melanoma prognostic factors and melanocytic nevus grading led to clinically significant changes in diagnosis leading to a change in patient management.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22521204     DOI: 10.1016/j.jaad.2012.02.036

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  Pathologists' Use of Second Opinions in Interpretation of Melanocytic Cutaneous Lesions: Policies, Practices, and Perceptions.

Authors:  Berta M Geller; Paul D Frederick; Stevan R Knezevich; Jason P Lott; Heidi D Nelson; Linda J Titus; Patricia A Carney; Anna N A Tosteson; Tracy L Onega; Raymond L Barnhill; Martin A Weinstock; David E Elder; Michael W Piepkorn; Joann G Elmore
Journal:  Dermatol Surg       Date:  2018-02       Impact factor: 3.398

2.  Diagnostic role of chromosomal instability in melanoma.

Authors:  Nitika Dabas; Diana M Byrnes; Ashley M Rosa; Mark S Eller; James M Grichnik
Journal:  J Skin Cancer       Date:  2012-10-18

3.  The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions.

Authors:  Clay Cockerell; Jaime Tschen; Steven D Billings; Brent Evans; Krystal Brown; Colleen Rock; Loren E Clarke
Journal:  Per Med       Date:  2017-01-23       Impact factor: 2.512

4.  An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.

Authors:  Loren E Clarke; Darl D Flake; Klaus Busam; Clay Cockerell; Klaus Helm; Jennifer McNiff; Jon Reed; Jaime Tschen; Jinah Kim; Raymond Barnhill; Rosalie Elenitsas; Victor G Prieto; Jonathan Nelson; Hillary Kimbrell; Kathryn A Kolquist; Krystal L Brown; M Bryan Warf; Benjamin B Roa; Richard J Wenstrup
Journal:  Cancer       Date:  2016-10-21       Impact factor: 6.860

5.  Assessment of a Diagnostic Classification System for Management of Lesions to Exclude Melanoma.

Authors:  Ian Katz; Blake O'Brien; Simon Clark; Curtis T Thompson; Brian Schapiro; Anthony Azzi; Alister Lilleyman; Terry Boyle; Lore Jane L Espartero; Miko Yamada; Tarl W Prow
Journal:  JAMA Netw Open       Date:  2021-12-01

6.  Reply to Reimann et al.

Authors:  Loren E Clarke; Sancy A Leachman
Journal:  Mod Pathol       Date:  2019-01-21       Impact factor: 7.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.